Spike-heparan sulfate interactions in SARS-CoV-2 infection
- PMID: 35926454
- PMCID: PMC9257145
- DOI: 10.1016/j.sbi.2022.102439
Spike-heparan sulfate interactions in SARS-CoV-2 infection
Abstract
Recent biochemical, biophysical, and genetic studies have shown that heparan sulfate, a major component of the cellular glycocalyx, participates in infection of SARS-CoV-2 by facilitating the so-called open conformation of the spike protein, which is required for binding to ACE2. This review highlights the involvement of heparan sulfate in the SARS-CoV-2 infection cycle and argues that there is a high degree of coordination between host cell heparan sulfate and asparagine-linked glycans on the spike in enabling ACE2 binding and subsequent infection. The discovery that spike protein binding and infection depends on both viral and host glycans provides insights into the evolution, spread and potential therapies for SARS-CoV-2 and its variants.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest J.D.E is a cofounder and T.M.C., and D.R.S. are consultants of Covicept Therapeutics, Inc. J.D.E. and the Regents of the University of California have licensed a university invention to and have an equity interest in TEGA Therapeutics, Inc., a vendor for heparan sulfate. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.
Figures
Similar articles
-
The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming.Proc Natl Acad Sci U S A. 2024 Oct 22;121(43):e2404892121. doi: 10.1073/pnas.2404892121. Epub 2024 Oct 14. Proc Natl Acad Sci U S A. 2024. PMID: 39401361
-
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.Cell. 2020 Nov 12;183(4):1043-1057.e15. doi: 10.1016/j.cell.2020.09.033. Epub 2020 Sep 14. Cell. 2020. PMID: 32970989 Free PMC article.
-
Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve In Vitro to Higher Infectivity through More Efficient Binding to Heparan Sulfate and Reduced S1/S2 Cleavage.J Virol. 2021 Oct 13;95(21):e0135721. doi: 10.1128/JVI.01357-21. Epub 2021 Aug 18. J Virol. 2021. PMID: 34406867 Free PMC article.
-
Structural basis of severe acute respiratory syndrome coronavirus 2 infection.Curr Opin HIV AIDS. 2021 Jan;16(1):74-81. doi: 10.1097/COH.0000000000000658. Curr Opin HIV AIDS. 2021. PMID: 33186231 Review.
-
Mechanism and evolution of human ACE2 binding by SARS-CoV-2 spike.Curr Opin Struct Biol. 2023 Aug;81:102619. doi: 10.1016/j.sbi.2023.102619. Epub 2023 May 15. Curr Opin Struct Biol. 2023. PMID: 37285618 Free PMC article. Review.
Cited by
-
The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming.Proc Natl Acad Sci U S A. 2024 Oct 22;121(43):e2404892121. doi: 10.1073/pnas.2404892121. Epub 2024 Oct 14. Proc Natl Acad Sci U S A. 2024. PMID: 39401361
-
Non-anticoagulant heparin derivatives for COVID-19 treatment.Int J Biol Macromol. 2023 Jan 31;226:974-981. doi: 10.1016/j.ijbiomac.2022.12.090. Epub 2022 Dec 14. Int J Biol Macromol. 2023. PMID: 36528145 Free PMC article. Review.
-
COVID-19 Biogenesis and Intracellular Transport.Int J Mol Sci. 2023 Feb 24;24(5):4523. doi: 10.3390/ijms24054523. Int J Mol Sci. 2023. PMID: 36901955 Free PMC article. Review.
-
Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection.Front Med (Lausanne). 2024 Mar 27;11:1364657. doi: 10.3389/fmed.2024.1364657. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38618194 Free PMC article. Review.
-
Well-Defined Heparin Mimetics Can Inhibit Binding of the Trimeric Spike of SARS-CoV-2 in a Length-Dependent Manner.JACS Au. 2023 Apr 6;3(4):1185-1195. doi: 10.1021/jacsau.3c00042. eCollection 2023 Apr 24. JACS Au. 2023. PMID: 37101566 Free PMC article.
References
-
- Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280 e278. - PMC - PubMed
-
This work was the defining paper describing ACE2 as a receptor for SARS-CoV-2 and that the serine protease TMPRSS2 was required for spike protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and was suggested as a treatment option.
-
- Clausen T.M., Sandoval D.R., Spliid C.B., Pihl J., Perrett H.R., Painter C.D., Narayanan A., Majowicz S.A., Kwong E.M., McVicar R.N., et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. 2020;183:1043–1057. - PMC - PubMed
-
This study investigated the binding of the SARS-CoV-2 spike protein to cellular heparan sulfate and the impact of this interaction on spike protein mediated viral infection. Compelling genetic and biochemical data demonstrated that heparan sulfate is a required co-receptor for SARS-CoV-2 infection in addition to ACE2.
-
- Zhang Q., Chen C.Z., Swaroop M., Xu M., Wang L., Lee J., Wang A.Q., Pradhan M., Hagen N., Chen L., et al. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov. 2020;6:80. - PMC - PubMed
-
This study showed that cellular heparan sulfate aids SARS-CoV-2 infection and that drugs that target heparan sulfate presentation are potential tools for SARS-CoV-2 treatment. Among the drugs characterized, Mitoxantrone was shown to be a potent HS inhibitor.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
